


# **COVID-19 Update** Dr Mark Cunningham-Hill Medical Director NEBGH

Monday June 21st, 2021

#### Daily new confirmed COVID-19 cases per million people




Shown is the rolling 7-day average. The number of confirmed cases is lower than the number of actual cases; the main reason for that is limited testing.




Source: Johns Hopkins University CSSE COVID-19 Data

CC B





#### States - Case rates vs. Vacinated 1st Dose






#### Daily new confirmed COVID-19 cases per million people



Shown is the rolling 7-day average. The number of confirmed cases is lower than the number of actual cases; the main reason for that is limited testing.




# **Delta Variant**

Delta variant


- Driving a surge in the UK
- More infectious
- ? More harmful
- Mostly un or partially vaccinated people getting ill
- Delta variant 10% of US cases up from 2.5% 3 weeks ago
- Vaccines once fully vaccinated people are protective against the Delta variant

Daily new confirmed COVID-19 cases per million people Shown is the rolling 7-day average. The number of confirmed cases is lower than the number of actual cases; the main reason for that is limited testing.



Rolling 7 day average of daily cases in England

📕 Other 📕 Delta variant (B.1.617.2 - first detected in India)




Source: BBC analysis of COG-UK and gov.uk data

BBC

Our World



#### Why did SARS-CoV-2 kill so many old people?





### Novelty = Severity

- When a virus is new, nobody possesses acquired immune protection against it
- Conventional wisdom was that influenza hit children and the elderly hardest, while sparing younger adults. Why was SARS-CoV-2 different?
- Severity is related to the age a person first meets a new virus: Look at virus severity not by age but by age of first infection
  - Children encounter many viruses to which they have no prior immunity. They compensate with robust innate immune responses that allow them to handle novel infections fairly well – Note: Robust doesn't equal invincible
  - As you get older you get less good at handling new viruses
  - When elderly you get less good at handling new and familiar viruses
  - Chickenpox benign in most children, but it's often severe in unlucky adults who make it to adulthood without being infected or vaccinated
  - OC43 one of the 'common cold' viruses generally mild but OC43 is thought to be the cause of the 1889/90 epidemic ("Russian Flu") that killed 1+M people it was novel then but now probably everyone exposed during childhood




# Transmissibility vs. Immune Dodging

- Alpha vs Beta?
- "More transmissible" is not benign when a virus is new; it's deadly
- More transmissible variants like Alpha, Gamma, and Delta are harder to control with PH measures
- The "Seychelles phenomenon"
- Global vaccine equity is not just a moral duty for wealthy countries like the USA; it's an emergency

#### COVID-19 vaccine doses administered per 100 people

Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).






Our World in Data

### Immunity is not an On/Off Switch

- Seasonal coronaviruses evolve over time "antigenic evolution"
- People suffer many influenza and Coronavirus infections over their lifetime - But until immunosenesnce, these reinfections rarely cause severe to critical illness, even when the virus has evolved partial immune escape
- Immune escape is rarely rapid and complete; it's more often gradual







### **Mixed Vaccines**

- Data from recent trials suggests mix and match COVID vaccine schedules may give higher antibody levels than two doses of a single vaccine.
- AZ/Oxford followed by a second shot with Pfizer
- Other studies ongoing with AZ/Oxford and Sputnik V
- Canada approved second dose with Pfizer vaccine after 1<sup>st</sup> dose with AZ/Oxford
- Several European countries are giving Pfizer or Moderna as second doses to AstraZeneca recipients





### **Antiviral Treatment**

- Only antiviral drug approved for treating COVID-19 is Remdesivir
- Merck has a new drug in phase II trials molnupiravir
  - Was not effective in hospitalized patients
  - Potential benefit if given within first 5 days of symptoms:
    - Lower rate of hospitalization and death than placebo
    - Among 202 treated participants:
      - Virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02)
      - At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03)
      - Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01).
      - Generally well tolerated, with similar numbers of adverse events across all groups
  - U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration





# Questions